Safety and Tolerability of Ultra-Rush (20 minutes) Sublingual Immunotherapy in Patients with Allergic Rhinitis and/or Asthma

Allergen immunotherapy: specific vaccines for allergic diseases. WHO position paper. Bousquet J, Lockey RF, Malling H-J, editors. Allergen immunotherapy: specific vaccines for allergic disease. WHO position paper. Allergy. 1998;53 Suppl:1-42. Lockey, 2001, “ARIA”. Global guidelines and new forms of allergen immunotherapy, J Allergy Clin Immunol, 108, 497, 10.1067/mai.2001.118638 Di Rienzo, 1999, Post-marketing surveillance study on the safety of sublingual immunotherapy in children, Allergy, 54, 1110, 10.1034/j.1398-9995.1999.00267.x Lombardi, 2001, Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study, Allergy, 56, 989, 10.1034/j.1398-9995.2001.00181.x Troise, 1995, Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double-blind study, J Invest Allergol Clin Immunol, 5, 25 Bousquet, 1999, Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study, Allergy, 54, 249, 10.1034/j.1398-9995.1999.00916.x Rossi, 2002, Safety of ultra-rush (two hours) sublingual-swallow immunotherapy in allergic patients, Giorn It Immunol Clin, 12, 221 Global strategy for asthma management and prevention. WHO/NHLBI workshop report. In: National Institutes of Health, National Heart, Lung and Blood Institute, Publication Number. 1995. p. 95-3659. Dreborg, 1993, Position Paper: Allergen standardization and skin tests, Allergy, 48, 49, 10.1111/j.1398-9995.1993.tb04756.x